Alternative therapeutic principles in the prevention of microvascular and neuropathic complications.
Since the prevention of chronic diabetic complications by near normal metabolic control is not always achievable, alternative therapeutic principles have been developed. The specific intervention at metabolic abnormalities which seem to play a key role in the pathogenesis of complications has been shown to prevent the development of microangiopathy and neuropathy in experimental diabetes, e.g. inhibition of non-enzymatic glycation by aminoguanidine, inhibition of polyol pathway activity by aldose reductase inhibitors, prevention of hypoxia and oxidative stress by vasodilators and radical scavengers such as alpha-lipoic acid. Some of these drugs should soon be available for common clinical use.
Gries
F A
FA
Diabetesforschungsinstitut an der Heinrich-Heine-Universität, Düsseldorf, Germany.
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology*; D003925:Diabetic Angiopathies / Q000517:prevention & control*; D003929:Diabetic Neuropathies / Q000517:prevention & control*; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D017127:Glycation End Products, Advanced / Q000037:antagonists & inhibitors; D006146:Guanidines / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D008954:Models, Biological; D018384:Oxidative Stress / Q000187:drug effects
D000975:Antioxidants; D004791:Enzyme Inhibitors; D017127:Glycation End Products, Advanced; D006146:Guanidines; D007004:Hypoglycemic Agents; D000449:Aldehyde Reductase; C004479:pimagedine